NYSE · LLY
Healthcare · Drug Manufacturers - General
$1,136.11
Down-$1.30 (-0.11%)
Updated Sep 16, 2026, 9:58 AM
SID Score
5.8/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LLY closed at $1,136.11 after 20 trading sessions, down 7.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1,156.63 | $1,161.00 | $1,131.59 | $1,136.11 | 1.89M |
| Sep 14, 2026 | $1,142.20 | $1,153.95 | $1,130.5001 | $1,138.28 | 2.13M |
| Sep 11, 2026 | $1,129.405 | $1,131.44 | $1,113.2919 | $1,115.70 | 1.84M |
| Sep 10, 2026 | $1,126.08 | $1,133.79 | $1,120.52 | $1,123.00 | 2M |
| Sep 9, 2026 | $1,127.61 | $1,138.79 | $1,119.00 | $1,124.21 | 2.05M |
| Sep 8, 2026 | $1,133.00 | $1,134.53 | $1,113.55 | $1,123.91 | 2.4M |
| Sep 4, 2026 | $1,150.61 | $1,158.44 | $1,138.306 | $1,149.36 | 2.22M |
| Sep 3, 2026 | $1,170.00 | $1,171.66 | $1,137.50 | $1,159.60 | 2.55M |
| Sep 2, 2026 | $1,164.15 | $1,187.83 | $1,158.00 | $1,160.08 | 2.45M |
| Sep 1, 2026 | $1,188.00 | $1,188.325 | $1,156.8501 | $1,160.00 | 2.52M |
| Aug 31, 2026 | $1,168.47 | $1,171.4479 | $1,147.00 | $1,156.73 | 3.06M |
| Aug 28, 2026 | $1,172.66 | $1,180.00 | $1,162.93 | $1,174.61 | 2.45M |
| Aug 27, 2026 | $1,182.25 | $1,190.11 | $1,171.71 | $1,176.10 | 2.74M |
| Aug 26, 2026 | $1,234.00 | $1,235.775 | $1,180.01 | $1,189.41 | 3.01M |
| Aug 25, 2026 | $1,249.00 | $1,264.73 | $1,229.79 | $1,233.66 | 2.14M |
| Aug 24, 2026 | $1,262.14 | $1,262.14 | $1,230.95 | $1,246.93 | 1.67M |
| Aug 21, 2026 | $1,232.00 | $1,271.22 | $1,230.00 | $1,255.40 | 2.5M |
| Aug 20, 2026 | $1,274.13 | $1,280.28 | $1,243.2301 | $1,244.40 | 2.62M |
| Aug 19, 2026 | $1,245.81 | $1,292.65 | $1,240.54 | $1,280.34 | 4.54M |
| Aug 18, 2026 | $1,200.00 | $1,228.47 | $1,194.01 | $1,225.73 | 2.51M |
The latest Smart Investors Daily articles mentioning LLY.
LLY research
Company profile and research snapshot.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Reduce | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Wells Fargo | Overweight | — |
| Aug 6, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 15, 2026 | Citigroup | Buy | — |
Generated Sep 15, 2026, 9:18 PM
Eli Lilly shares are essentially flat, down just 0.11%, as investors digest a wave of bullish analyst upgrades offset by intensifying competitive pressures in the obesity drug market. The mixed sentiment reflects growing confidence in LLY's pipeline while acknowledging headwinds from Novo Nordisk's strategic repositioning and broader market adoption challenges.
Bottom line: Eli Lilly is caught between compelling long-term fundamentals—validated by high-profile analyst upgrades and strong commercial traction in oral weight-loss drugs—and near-term execution uncertainties in a rapidly evolving competitive landscape. Investors should monitor upcoming European data presentations closely, while remaining cognizant of pricing pressures and market adoption risks as multiple players expand into adjacent GLP-1 applications.
Yahoo · Sep 16, 2026
A powerful drug pipeline is fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, but the ticket price for investors is steep and the clock is ticking on its biggest star.
Yahoo · Sep 15, 2026
One fast-growing business could push results above guidance
Yahoo · Sep 15, 2026
The drugmaker has a lot riding on continued clinical progress.
Yahoo · Sep 15, 2026
Thatch, the health benefits platform helping employers move from traditional group health plans to a consumer-directed model, today announced that it has raised $108 million in new funding at a $1 billion valuation from The General Partnership, Index Ventures, General Catalyst, and Andreessen Horowitz, with participation from ADP Ventures, Paychex, Eli Lilly and Company, Scale Venture Partners, QuantumLight, SemperVirens, Quiet Capital, and Avid Ventures.
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company shares traded at $1,137.75, reflecting a single-day decline of 1.66% per SID market data. Over the trailing one-month period, LLY has declined 5.85%, though the stock has posted a modest 0.47% gain over three months and a robust 14.56% return over the past twelve months. The stock currently trades below its 50-day moving average of $1,183.14 but remains well above its 200-day moving average of $1,060.24, according to SID market data. Notably, the 14-day relative strength index has fallen to 16.3, placing LLY deep in oversold territory and signaling sustained near-term selling pressure. The company maintains a market capitalization of approximately $906.5 billion. LLY exhibits a beta of 0.369, indicating significantly lower volatility relative to the broader market. Average daily trading volume stands at approximately 3.8 million shares, reflecting consistent institutional participation in the name.
Eli Lilly currently trades at a price-to-earnings ratio of 49.16, a significant premium relative to the broader Healthcare sector, reflecting the market's pricing of the company's high-growth pharmaceutical pipeline, per SID market data. The PEG ratio stands at 1.47, according to SID market data, suggesting the valuation is moderately stretched relative to expected earnings growth, though still within a range often considered reasonable for high-growth biopharma companies. The price-to-book ratio of 38.04 further underscores the premium investors assign to Eli Lilly's intangible assets, including its GLP-1 franchise and pipeline optionality. The company offers a dividend yield of approximately 0.59%, per SEC filings, positioning it as a modest income contributor rather than a yield-driven holding. The combination of elevated earnings and book value multiples indicates the market continues to embed substantial future revenue and earnings expansion into LLY's current share price.
Eli Lilly's composite smart money score stands at 46 out of 100, registering a neutral signal per SID market data. The institutional component scores a perfect 25 out of 25, indicating maximum institutional ownership conviction and consistent accumulation among large fund managers, according to 13F institutional filings. In contrast, the insider activity score is notably weak at 4.1 out of 25, despite a relatively balanced transaction profile of 5 insider purchases versus 4 insider sales across 9 total trades recorded over the last 90 days, per SEC Form 4 filings. The dark pool activity score of 9.2 out of 25 suggests below-average off-exchange buying interest, while the congressional trading component registers at 7.6 out of 25, reflecting limited disclosed activity by members of Congress. The divergence between strong institutional conviction and weaker insider and dark pool signals creates a mixed overall positioning profile, warranting close monitoring of subsequent Form 4 filings for directional shifts in insider sentiment.
Eli Lilly has delivered consecutive earnings beats across its three most recently reported quarters, according to company earnings reports. In the most recent quarter reported on April 30, 2026, the company posted earnings per share of $8.55, exceeding the consensus estimate of $6.85 by $1.70. The prior quarter, reported on February 4, 2026, saw EPS of $7.54 versus the $6.96 estimate, representing a $0.58 positive surprise. The strongest beat came in the August 5, 2026 report, where actual EPS of $8.38 surpassed the $6.01 estimate by $2.37. Looking ahead, the next scheduled earnings release is August 6, 2026, with analysts projecting EPS of $8.84, per analyst estimates. The upward trajectory in both actual earnings and consensus expectations reflects continued revenue acceleration, particularly from the company's high-demand metabolic disease portfolio. The pattern of consistent outperformance suggests analysts may still be underestimating operational momentum.
Wall Street coverage of Eli Lilly remains predominantly bullish, with four of the five most recent analyst actions carrying positive ratings, per Wall Street analyst reports. Truist Securities reiterated its Buy rating on August 7, 2026, while both Wells Fargo and Cantor Fitzgerald maintained Overweight ratings on August 6, 2026, following the company's earnings release. Citigroup also reiterated its Buy rating on July 15, 2026, according to SID consensus data. The sole dissenting voice comes from HSBC, which maintained its Reduce rating on September 10, 2026, representing the only bearish call among recent coverage updates. Notably, all five actions were reiterations of prior ratings rather than upgrades or downgrades, indicating stable analyst conviction levels. The strong consensus skew toward Buy and Overweight ratings reflects broad institutional confidence in Eli Lilly's revenue growth trajectory and pipeline execution. The 4-to-1 ratio of bullish to bearish ratings underscores the prevailing constructive sentiment among sell-side analysts covering the name.
The latest Smart Investors Daily articles mentioning LLY.
